initial public offerings (IPOs) trading on American exchanges

Thursday, March 28, 2019

Precision BioSciences (DTIL) began trading on the Nasdaq on Thur 28 March 2019

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. 
The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection.

Precision BioSciences (DTIL) priced 7.9 mln share IPO at $16.00 per share, the midpoint of the expected $15-17 per share range
Opened for trading at $18.00

No comments:

Post a Comment